Amylyx’s ALS drug slows disease progression in Phase II trial
ALS is a neurodegenerative disease impacting nerve cells in the brain and spinal cord. Credit: Sabine Zierer from Pixabay.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more